

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended June 30, 2010

☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Transition Period from _____ to _____
Commission File Number 0-23272



NPS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of Incorporation or Organization)

87-0439579
(I.R.S. Employer Identification No.)

550 Hills Drive, Bedminster, New Jersey
(Address of Principal Executive Offices)

07921
(Zip Code)

(908) 450-5300

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for at least the past 90 days. YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES ☐ NO ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," and large "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input checked="" type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒

The number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date is as follows:

Class	Outstanding at July 28, 2010
Common Stock \$.001 par value	58,970,925

TABLE OF CONTENTS

	<u>Page No.</u>
PART I FINANCIAL INFORMATION	
Item 1. Financial Statements (unaudited)	
<u>Condensed Consolidated Balance Sheets</u>	3
<u>Condensed Consolidated Statements of Operations</u>	4
<u>Condensed Consolidated Statements of Cash Flows</u>	5
<u>Notes to Condensed Consolidated Financial Statements</u>	6
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	19
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	27
Item 4. <u>Controls and Procedures</u>	28
PART II OTHER INFORMATION	
Item 1. <u>Legal Proceedings</u>	29
Item 1A. <u>Risk Factors</u>	29
Item 6. <u>Exhibits</u>	30
<u>SIGNATURES</u>	

PART 1
FINANCIAL INFORMATION

Item 1. Financial Statements.

NPS PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)

	<u>June 30, 2010</u>	<u>December 31, 2009</u>
Assets		
Current assets:		
Cash and cash equivalents	\$ 69,246	\$ 18,276
Marketable investment securities	63,995	56,652
Restricted cash and cash equivalents	15,166	41,821
Accounts receivable	26,843	23,965
Prepaid expenses	3,752	2,458
Other current assets	1,483	2,080
Total current assets	<u>180,485</u>	<u>145,252</u>
Equipment, net	466	399
Goodwill	9,429	9,429
Debt issuance costs, net	2,836	3,454
Other assets	563	1,058
Total assets	<u>\$ 193,779</u>	<u>\$ 159,592</u>
Liabilities and Stockholders' Deficit		
Current liabilities:		
Accounts payable and accrued expenses	\$ 23,688	\$ 25,458
Current portion of non-recourse debt and capital lease obligation	27,827	48,514
Total current liabilities	<u>51,515</u>	<u>73,972</u>
Convertible notes payable	50,000	50,000
Non-recourse debt, less current portion	259,996	240,194
Other liabilities	11,785	18,225
Total liabilities	<u>373,296</u>	<u>382,391</u>
Commitments and contingencies (notes 7, 9 and 10)		
Stockholders' deficit:		
Preferred stock, \$0.001 par value. Authorized 5,000,000 shares; issued and outstanding no shares	-	-
Common stock, \$0.001 par value. Authorized 105,000,000 shares; issued and outstanding 58,970,925 shares and 48,427,880 shares, respectively	59	48
Additional paid-in capital	752,488	697,002
Accumulated other comprehensive income	31	2,893
Accumulated deficit	<u>(932,095)</u>	<u>(922,742)</u>
Total stockholders' deficit	<u>(179,517)</u>	<u>(222,799)</u>
Total liabilities and stockholders' deficit	<u>\$ 193,779</u>	<u>\$ 159,592</u>

See accompanying notes to condensed consolidated financial statements.

NPS PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations (In thousands, except per share data) (Unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2010	2009	2010	2009
Revenues:				
Royalties	\$ 23,969	\$ 22,827	\$ 41,758	\$ 37,235
Product sales	50	8	534	8
Milestones and license fees	-	2,814	2,025	4,735
Total revenues	<u>24,019</u>	<u>25,649</u>	<u>44,317</u>	<u>41,978</u>
Operating expenses:				
Cost of license fees	-	123	6	481
Research and development	15,799	6,427	25,307	12,259
General and administrative	4,193	4,981	8,490	9,534
Total operating expenses	<u>19,992</u>	<u>11,531</u>	<u>33,803</u>	<u>22,274</u>
Operating income	<u>4,027</u>	<u>14,118</u>	<u>10,514</u>	<u>19,704</u>
Other income (expense):				
Interest income	89	400	239	1,000
Interest expense	(11,206)	(11,800)	(24,546)	(27,491)
Gain on sale of marketable investment securities	99	-	3,751	-
Loss on impairment of marketable investment securities	-	-	-	(2,206)
Foreign currency gain (loss)	530	(120)	591	(174)
Other	160	19	98	34
Total other expense, net	<u>(10,328)</u>	<u>(11,501)</u>	<u>(19,867)</u>	<u>(28,837)</u>
(Loss) income before income tax benefit	<u>(6,301)</u>	<u>2,617</u>	<u>(9,353)</u>	<u>(9,133)</u>
Income tax benefit	-	-	-	(1,014)
Net (loss) income	<u>\$ (6,301)</u>	<u>\$ 2,617</u>	<u>\$ (9,353)</u>	<u>\$ (8,119)</u>
Net (loss) income per common and potential common share				
Basic	\$ (0.11)	\$ 0.05	\$ (0.18)	\$ (0.17)
Diluted	\$ (0.11)	\$ 0.05	\$ (0.18)	\$ (0.17)
Weighted average common and potential common shares outstanding:				
Basic	57,166	48,017	53,126	47,988
Diluted	57,166	48,034	53,126	47,988

See accompanying notes to condensed consolidated financial statements.

NPS PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)

	Six Months Ended June 30,	
	2010	2009
Cash flows from operating activities:		
Net loss	\$ (9,353)	\$ (8,119)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	61	75
Accretion of premium (discount) on marketable investment securities	362	(17)
Recognized loss on impairment of marketable investment securities	-	2,206
Non-cash interest expense	18,783	14,693
Non-cash reduction in interest accrual/change in royalty receivable	(6,940)	(4,476)
Realized/recognized gain on marketable investment securities	(3,797)	(24)
Compensation expense on share based awards	1,623	1,556
(Increase) decrease in operating assets:		
Accounts receivable	(3,983)	1,131
Prepaid expenses, other current assets and other assets	(204)	(611)
Increase (decrease) in operating liabilities:		
Accounts payable and accrued expenses	(309)	(9,976)
Deferred revenue	-	(2,494)
Other liabilities	(6,440)	666
Net cash used in operating activities	<u>(10,197)</u>	<u>(5,390)</u>
Cash flows from investing activities:		
Sales of marketable investment securities	9,271	-
Maturities of marketable investment securities	34,880	17,645
Purchases of marketable investment securities	(50,902)	(28,684)
Acquisitions of equipment	(166)	(240)
Net cash used in investing activities	<u>(6,917)</u>	<u>(11,279)</u>
Cash flows from financing activities:		
Principal payments on debt and capital lease obligation	(50,662)	(35,358)
Proceeds from issuance of non-recourse debt	38,400	-
Payment of debt issuance costs	(166)	-
Proceeds from the sale of common stock and exercise of stock options	53,858	172
Decrease in restricted cash and cash equivalents	26,655	27,251
Net cash provided by (used in) financing activities	<u>68,085</u>	<u>(7,935)</u>
Effect of exchange rate changes on cash	<u>(1)</u>	<u>55</u>
Net increase (decrease) in cash and cash equivalents	50,970	(24,549)
Cash and cash equivalents at beginning of period	18,276	50,834
Cash and cash equivalents at end of period	<u>\$ 69,246</u>	<u>\$ 26,285</u>
<i>Supplemental Disclosures of Cash Flow Information:</i>		
Cash paid for interest	\$ 12,799	\$ 20,169
Cash paid for income taxes	-	-
<i>Supplemental Disclosure of Non-cash Investing and Financing Activities:</i>		
Unrealized losses on marketable investment securities	(81)	(628)
Accrued acquisition of equipment	(38)	(55)
Debt issued in lieu of interest	11,377	9,772

See accompanying notes to condensed consolidated financial statements.

NPS PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

(1) Basis of Presentation

The accompanying unaudited condensed consolidated financial statements included herein have been prepared by NPS Pharmaceuticals, Inc. (NPS or the Company) in accordance with the rules and regulations of the United States Securities and Exchange Commission (SEC). The condensed consolidated financial statements are comprised of the financial statements of NPS and its subsidiaries collectively referred to as the Company. In management's opinion, the interim financial data presented includes all adjustments (consisting solely of normal recurring items) necessary for fair presentation. All intercompany accounts and transactions have been eliminated. Certain information required by U.S. generally accepted accounting principles has been condensed or omitted in accordance with rules and regulations of the SEC. Operating results for the three and six months ended June 30, 2010 are not necessarily indicative of the results that may be expected for any future period or the year ending December 31, 2010.

These condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and the notes thereto for the year ended December 31, 2009, included in NPS' 2009 Annual Report on Form 10-K filed with the SEC.

The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions relating to reporting of the assets and liabilities and the disclosure of contingent assets and liabilities to prepare these condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period in conformity with U.S. generally accepted accounting principles. Actual results could differ from these estimates.

Subsequent Events

The Company has evaluated all events and transactions since June 30, 2010. The Company did not have any material recognized or non-recognized subsequent events.

(2) Income (Loss) Per Common Share

The following table presents basic and diluted net income per common share for the three months ended June 30, 2009. Diluted net loss per common share is the same as basic net loss per common share for the three months ended June 30, 2010 and the six months ended June 30, 2010 and 2009.

		Three Months Ended June 30, 2009
EPS Numerator – Basic:		
Net income	\$	2,617
EPS Denominator – Basic:		
Weighted-average number of shares of common stock outstanding		48,017
EPS Numerator – Diluted:		
Net income	\$	2,617
EPS Denominator – Diluted:		
Weighted-average number of shares of common stock outstanding		48,017
Effect of dilutive securities:		
Stock options		-
Restricted stock units		17
Dilutive potential common shares		17
Weighted-average common shares and dilutive potential common shares		48,034
Basic net income per common share	\$	0.05
Diluted net income per common share	\$	0.05

Basic net income (loss) per common share is the amount of income (loss) for the period divided by the weighted average shares of common stock outstanding during the reporting period. Diluted income (loss) per common share is the amount of income (loss) for the period plus interest expense on convertible debt divided by the sum of weighted average shares of common stock outstanding during the reporting period and weighted average shares that would have been outstanding assuming the issuance of common shares for all dilutive potential common shares.

Potential common shares of approximately 11.8 million and 13.7 million during the three and six months ended June 30, 2010, respectively and 14.5 million and 13.9 million during the three and six months ended June 30, 2009, respectively that could potentially dilute basic income per share in the future were not included in the computation of diluted income (loss) per share because to do so would have been anti-dilutive for the periods presented. Potential dilutive common shares related to convertible debt were approximately 9.2 million common shares for the three and six months ended June 30, 2010 and 2009. Additionally, potential dilutive common shares related to stock options, restricted stock and restricted stock units were 2.6 million and 4.5 million common shares, for the three and six months ended June 30, 2010, respectively, and 5.3 million and 4.7 million common shares, for the three and six months ended June 30, 2009, respectively.

(3) Fair Value Measurement

In September 2009, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2010-06, “*Fair Value Measurements and Disclosures (Topic 820): Improving Disclosures about Fair Value Measurements.*” ASU 2009-06 amends certain disclosure requirements of Subtopic 820-10. This ASU provides additional disclosures for transfers in and out of Levels 1 and 2 and for activity in Level 3. This ASU also clarifies certain other existing disclosure requirements including level of desegregation and disclosures around inputs and valuation techniques. The Company adopted ASU 2010-06 on January 1, 2010. The new disclosures about purchases, sales, issuances, and settlements in the roll forward activity for Level 3 fair-value measurements are effective for fiscal years beginning after December 15, 2010 and the Company will adopt this provision effective January 1, 2011.

Summary of Assets Recorded at Fair Value

The Company's financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows:

Level 1- Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 2- Inputs are other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).

Level 3- Inputs are unobservable and reflect the Company's assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available.

In accordance with the fair value hierarchy described above, the following table shows the fair value of the Company's financial assets (all marketable investment securities) that are required to be measured at fair value as of June 30, 2010 and December 31, 2009 (in thousands):

<i>As of June 30, 2010:</i>	Level 1	Level 2	Level 3	Total
Marketable investment securities	\$ 53,701	\$ 9,944	\$ 350	\$ 63,995

<i>As of December 31, 2009:</i>	Level 1	Level 2	Level 3	Total
Marketable investment securities	\$ 36,070	\$ 11,996	\$ 8,586	\$ 56,652

As of June 30, 2010 and December 31, 2009, the fair values of the Company's Level 2 securities were \$9.9 million and \$12.0 million, respectively. These securities are certificates of deposit or commercial paper issued by domestic companies with an original maturity of greater than ninety days. These securities are currently rated A-1 or higher. The Company's cash equivalents are classified within Level 1 or Level 2 of the fair value hierarchy because they are valued using quoted market prices or broker or dealer quotations for similar assets.

As of June 30, 2010 and December 31, 2009, the fair values of the Company's Level 3 securities were \$350,000 and \$8.6 million, respectively. The Level 3 securities are investments in Auction Rate Securities ("ARS") for which the auctions had failed since 2008. The Level 3 securities at June 30, 2010 have been valued at par due to the agreement with our investment advisor which allows us to sell the ARS back to the investment advisor on July 1, 2010 at par. Prior to June 30, 2010, when estimating the fair value of the ARS, the Company used the fair values which were determined based on valuations performed by Pluris Valuation Advisors LLC. The fair values were determined using proprietary valuation models using the quality of the underlying securities or assets securing the ARS investments, the fair values of comparable securities, the quality of credit enhancement (if any) applicable to the specific security, estimated time to maturity or unwinding of the arrangement, an analysis of the terms of the indentures and other factors depending on the individual ARS.

There were no transfers of assets or liabilities between level 1 and level 2 during the first six months of 2010.

The following table summarizes the changes in fair value of the Company's Level 3 assets (in thousands):

	For the Three Months Ended		For the Six Months Ended	
	June 30,		June 30,	
	2010	2009	2010	2009
Beginning balance	\$ 904	\$ 6,548	\$ 8,586	\$ 8,752
Total gains (losses) (realized or unrealized)				
Included in earnings	146	22	3,816	(2,182)
Included in other comprehensive income	-	1,773	(2,781)	1,773
Transfers in (out) of Level 3	-	-	-	-
Sales	(700)	-	(9,271)	-
Ending balance	<u>\$ 350</u>	<u>\$ 8,343</u>	<u>\$ 350</u>	<u>\$ 8,343</u>
Losses included in earnings attributable to change in unrealized gains or losses (including other-than-temporary impairments) relating to assets still held at the reporting date	\$ -	\$ (22)	\$ -	\$ 2,182

The carrying amounts reflected in the condensed consolidated balance sheets for certain short-term financial instruments including cash equivalents, restricted cash equivalents, accounts receivable, accounts payable, accrued expenses, and other liabilities approximate fair value due to their short-term nature except that the estimated fair value and carrying value of the Brigham and Women's Hospital royalty liability using a discounted cash flow model is approximately \$4.7 million and \$8.6 million, respectively, at June 30, 2010 and \$5.4 million and \$9.6 million, respectively, at December 31, 2009.

Summary of Liabilities Recorded at Carrying Value

The fair and carrying value of our debt instruments are detailed as follows (in thousands):

	As of June 30, 2010		As of December 31, 2009	
	Fair Value	Carrying Value	Fair Value	Carrying Value
5.75% Convertible Notes	\$ 58,218	\$ 50,000	\$ 47,599	\$ 50,000
8.0% Non-recourse Notes - Class A	48,491	46,182	100,363	94,682
15.5% Non-recourse Notes - Class B	132,081	155,389	122,410	144,012
Total	<u>\$ 238,790</u>	<u>\$ 251,571</u>	<u>\$ 270,372</u>	<u>\$ 288,694</u>

The fair values of the Company's convertible notes were estimated using the (i) terms of the convertible notes; (ii) rights, preferences, privileges, and restrictions of the underlying security; (iii) time until any restriction(s) are released; (iv) fundamental financial and other characteristics of the Company; (v) trading characteristics of the underlying security (exchange, volume, price, and volatility); and (vi) precedent sale transactions. The fair values of the Company's non-recourse notes were estimated using market observable inputs, including quoted prices and market indices. Within the hierarchy of fair value measurements, these are Level 2 fair values.

(4) Financial Instruments

Financial instruments that potentially subject the Company to concentrations of credit risk are accounts receivable and marketable investment securities. The majority of the Company's accounts receivable are payable by large pharmaceutical companies and collateral is generally not required from these companies. Substantially all of the Company's revenues for the three and six months ended June 30, 2010 and 2009 were from four licensees of the Company. At June 30, 2010 and December 31, 2009, substantially all of the Company's accounts receivable balances were from four licensees. The Company's portfolio of marketable investment securities is subject to concentration limits set within the Company's investment policy that help to mitigate its credit exposure.

The Company's investment portfolio includes investments in certain auction-rate securities ("ARS"). ARS are variable interest rate securities tied to short-term interest rates with nominal long-term maturities. ARS have interest rate resets through a modified Dutch auction, at predetermined short-term intervals, usually every 7, 28, 35,

or 49 days. With the liquidity issues experienced in global credit and capital markets, the Company's ARS portfolio continues to experience unsuccessful auctions as the amount of securities submitted for sale has exceeded the amount of purchase orders. Given the unsuccessful auctions, the Company's ARS are illiquid and will be until there is a successful auction for them or the Company can sell them to a third-party.

In October 2008, the Company entered into a settlement agreement to sell certain of its ARS back to its investment advisor no later than July 1, 2010 at par of \$1.8 million, and the Company transferred these ARS from the available for sale category to the trading category. During November 2009, one of these ARS was called at par of \$350,000. During the six months ended June 30, 2010, three additional ARS were called at par of \$350,000 each and the Company recognized a gain of \$99,000 and \$161,000 during the three and six months ended June 30, 2010, respectively. The fair values of the ARS are \$350,000 and \$1.2 million at June 30, 2010 and December 31, 2009, respectively. Per the settlement agreement described above, the Company sold the remaining ARS to its investment advisor on July 1, 2010. The Company has recognized \$0 and \$222,000 as a put option in other current assets at June 30, 2010 and December 31, 2009, respectively and a loss of \$145,000 and \$222,000 in other income (expense) for the three and six months ended June 30, 2010 and a loss of \$3,000 and a gain of \$11,000 in other income (expense) for the three and six months ended June 30, 2009. The Company elected the fair value measurement option for its ARS put option. The fair value election was made to minimize the net volatility of earnings in future periods as the change in fair value of the put option will approximate the opposite change in fair value of the related ARS. In estimating the fair value of this put option, the Company used the fair values which were determined based on valuations performed by Pluris Valuation Advisors LLC. The fair values were determined using proprietary valuation models.

In February 2010, the Company sold certain ARS securities to a third-party with the principal value of \$23.5 million and cost basis of \$4.6 million for \$8.2 million, excluding the ARS subject to the settlement agreement discussed above. The Company recognized a gain of \$0 and \$3.6 million during the three and six months ended June 30, 2010 related to the sale of these ARS.

The following is a summary of the Company's cash, cash equivalents and available for sale marketable investment securities (in thousands):

	Amortized cost	Gross unrealized holding gains	Gross unrealized holding losses	Fair value
<i>As of June 30, 2010:</i>				
Cash and Cash Equivalents:	\$ 69,246	\$ 1	\$ (1)	\$ 69,246
Marketable Investment Securities:				
Available for Sale:				
Debt securities:				
Corporate	\$ 29,321	\$ 13	\$ (28)	\$ 29,306
Government agency	34,339	9	(9)	34,339
Total investments in marketable securities	\$ 63,660	\$ 22	\$ (37)	\$ 63,645
	Amortized cost	Gross unrealized holding gains	Gross unrealized holding losses	Fair value
<i>As of December 31, 2009:</i>				
Cash and Cash Equivalents:	\$ 18,281	\$ -	\$ (5)	\$ 18,276
Marketable Investment Securities:				
Available for Sale:				
Debt securities:				
Corporate	\$ 17,346	\$ 59	\$ (6)	\$ 17,399
Auction rate securities	4,632	2,780	-	7,412
Government agency	30,649	31	(13)	30,667
Total investments in marketable securities	\$ 52,627	\$ 2,870	\$ (19)	\$ 55,478

Marketable investment securities available for sale in an unrealized loss position as of June 30, 2010 and December 31, 2009 are summarized as follows (in thousands):

	Held for less than 12 months		Held for more than 12 months		Total	
	Fair value	Unrealized losses	Fair value	Unrealized losses	Fair value	Unrealized losses
As of June 30, 2010:						
Available for Sale:						
Debt securities:						
Corporate	\$ 25,545	\$ 28	\$ -	\$ -	\$ 25,545	\$ 28
Government agency	3,053	9	-	-	3,053	9
	<u>\$ 28,598</u>	<u>\$ 37</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 28,598</u>	<u>\$ 37</u>

As of December 31, 2009:

Available for Sale:

Debt securities:

Corporate	\$ 6,603	\$ 6	\$ -	\$ -	\$ 6,603	\$ 6
Government agency	22,750	13	-	-	22,750	13
	<u>\$ 29,353</u>	<u>\$ 19</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 29,353</u>	<u>\$ 19</u>

Summary of Contractual Maturities

Maturities of marketable investment securities are as follows at June 30, 2010 and December 31, 2009 (in thousands):

	As of June 30, 2010		As of December 31, 2009	
	Amortized cost	Fair value	Amortized cost	Fair value
Due within one year	\$ 64,010	\$ 63,995	\$ 49,169	\$ 49,240
Due after one year through five years	-	-	-	-
Due after five years through ten years	-	-	-	-
Due after ten years	-	-	4,632	7,412
Total debt securities	<u>\$ 64,010</u>	<u>\$ 63,995</u>	<u>\$ 53,801</u>	<u>\$ 56,652</u>

Impairments

No impairment losses were recognized through earnings related to available for sale securities during the three and six months ended June 30, 2010.

No impairment losses were recognized through earnings related to available for sale securities during the three months ended June 30, 2009. During the six months ended June 30, 2009, the Company recognized \$2.2 million in charges for the impairment of available for sale securities primarily related to auction rate securities due to the duration of time for which the securities have been in a loss position and the severity of the decline in fair value.

Proceeds from Marketable Investment Securities

The proceeds from maturities and sales of marketable investment securities and resulting realized gains and losses, were as follows (in thousands):

	For the Three Months		For the Six Months	
	Ended June 30,		Ended June 30,	
	2010	2009	2010	2009
Proceeds from sales and maturities	\$ 17,230	\$ 9,145	\$ 44,151	\$ 17,645
Realized gains	99	-	3,751	-
Realized losses	-	-	-	-

The realized gains for the three and six months ended June 30, 2010 primarily related to the sale of ARS and the realized gains for the three and six months ended June 30, 2009 primarily related to the sale of corporate debt securities.

(5) Collaborations

The Company is pursuing product development both on an independent basis and in collaboration with others. Because the Company has granted exclusive development, commercialization, and marketing rights under certain of the below-described collaborative research, development, and license agreements, the success of each program is dependent upon the efforts of the licensees. Each of the respective agreements may be terminated early. If any of the licensees terminate an agreement, such termination may have a material adverse effect on the Company's operations.

Certain transactions between collaborators will be recorded in the income statement on either a gross or net basis, depending on the characteristics of the collaboration relationship. Amounts due from the Company's collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company's operations. For collaborations with commercialized products, if the Company is the principal, the Company records revenue and the corresponding operating costs in their respective line items within the Company's condensed consolidated statements of operations. If the Company is not the principal, the Company records operating costs as a reduction of revenue. The principal is the party who is responsible for delivering the product or service to the customer, has latitude with establishing price, and has the risks and rewards of providing product or service to the customer, including inventory and credit risk.

A description of significant current collaborations and license agreements appears below:

(a) Amgen Inc.

The Company has a development and license agreement with Amgen to develop and commercialize compounds for the treatment of hyperparathyroidism and indications other than osteoporosis. Amgen also acquired an equity investment in the Company in 1995. Amgen paid the Company a \$10.0 million nonrefundable license fee and agreed to pay up to \$400,000 per year through 2000 in development support, potential additional development milestone payments totaling \$26.0 million, and royalties on any future product sales. Through June 30, 2010, Amgen has paid the Company \$21.0 million in milestone payments. Amgen is incurring all costs of developing and commercializing these products. Amgen received exclusive worldwide rights excluding Japan, China, Korea, and Taiwan. The Company recognized royalties from product sales of \$20.3 million and \$19.4 million for the three months ended June 30, 2010 and 2009, respectively and \$34.4 million and \$31.0 million for the six months ended June 30, 2010 and 2009, respectively, under the agreement. The Company also recognized milestone revenue of \$0 and \$2.0 million for the three and six months ended June 30, 2010, respectively, and no milestone revenue during the three and six months ended June 30, 2009, under the agreement.

(b) Kyowa Hakko Kirin

In 1995, the Company entered into an agreement with the pharmaceutical division of Kyowa Hakko Kirin, formerly Kirin Pharma, to develop and commercialize compounds for the treatment of hyperparathyroidism in Japan, China, Korea, and Taiwan. Kyowa Hakko Kirin paid the Company a \$5.0 million license fee and agreed to

pay up to \$7.0 million in research support, potential additional milestone payments totaling \$13.0 million and royalties on product sales. Kyowa Hakko Kirin is incurring all costs of developing and commercializing products. Any payments subsequent to June 2000 represent milestone and royalty payments. Through June 30, 2010, Kyowa Hakko Kirin has paid the Company \$13.0 million in milestone payments. The Company recognized milestones and license fee revenue of \$0 in the three and six months ended June 30, 2010 and 2009. The Company recognized royalty revenue of \$1.3 million and \$885,000 for the three months ended June 30, 2010 and 2009, respectively and \$2.5 million and \$1.6 million for the six months ended June 30, 2010 and 2009, respectively

(c) Nycomed

Teduglutide

In September 2007 the Company entered into a license agreement with Nycomed Danmark ApS (Nycomed) in which the Company granted Nycomed the right to develop and commercialize teduglutide outside the United States, Canada and Mexico for the treatment of gastrointestinal disorders. Teduglutide, a proprietary analog of GLP-2, is being evaluated by NPS as GATTEX® (planned brand name) in the U.S. in a Phase 3 registration study known as STEPS for intestinal failure associated with short bowel syndrome and in preclinical development for chemotherapy-induced gastrointestinal mucositis and other pediatric indications. The Company received \$35.0 million in up-front fees under the agreement. Nycomed paid the Company \$10.0 million upon signing the license agreement and paid the Company an additional \$25.0 million in up-front license fees in the fourth quarter of 2007. Under the terms of the agreement, the Company has the potential to earn up to \$180.0 million in development and sales milestone payments plus royalties on product sales. Under the terms of the agreement, the Company was responsible to complete the first Phase 3 clinical trial in SBS and Nycomed may elect to share equally in the future development costs with NPS to advance and broaden the indications for teduglutide. Additionally, under a previously existing licensing agreement with a third-party, the Company paid \$6.6 million in 2007 to the licensor and will be required to make future payments based on teduglutide royalties and milestone payments earned. Due to the Company's continuing involvement, the Company recognized revenue associated with the upfront fees over the estimated performance period and for the three months ended June 30, 2010 and 2009, the Company recognized \$0 and \$624,000 in license fee revenue, respectively and \$0 and \$2.5 million and for the six months ended June 30, 2010 and 2009, respectively. The performance period ended on May 4, 2009 and therefore, the up-front license fee was fully recognized as revenue as of June 30, 2009.

In December 2008, Nycomed and the Company agreed to share equally in certain external clinical costs incurred by both companies, including those related to a second Phase 3 study of teduglutide in short bowel syndrome. Reimbursements from Nycomed for their portion of the research and development activities are characterized as a reduction of the Company's research and development costs because performing contract research and development services is not central to the Company's operations.

Preotact® (parathyroid hormone 1-84)

In 2004, the Company signed a distribution and license agreement with Nycomed in which the Company granted Nycomed the right to develop and market Preotact® (recombinant parathyroid hormone 1-84) in Europe. Nycomed also acquired an equity investment in the Company of \$40.0 million through the purchase of 1.33 million shares of the Company's common stock. The agreement requires Nycomed to pay the Company up to 20.8 million Euros in milestone payments upon regulatory approvals and achievement of certain sales targets and pay the Company royalties on product sales. In July 2007, the Company entered into a new license agreement with Nycomed, pursuant to which the Company granted to Nycomed the right to commercialize Preotact in all non-U.S. territories, excluding Japan and Israel; however, Nycomed's licensed rights in Canada and Mexico, revert back to the Company if the Company receives regulatory approval for the compound in the U.S. The 2007 license agreement contains milestone and royalty payment obligations which are similar to those under the 2004 distribution and license agreement. Nycomed is required to pay the Company royalties on sales of Preotact only in the European Union, the Commonwealth of Independent States and Turkey. The 2007 license agreement provides for the assumption by Nycomed of NPS' manufacturing and supply obligations and patent prosecution and maintenance obligations under the 2004 license agreement, which occurred in 2008. As part of the manufacturing and supply transfer, Nycomed paid the Company \$11.0 million during 2007, for a significant portion of the Company's existing bulk drug inventory. Through June 30, 2010, the Company has received 7.1 million Euros in milestone payments from Nycomed under the 2004 and 2007 agreements, all of which have been recognized as revenue.

Revenues from Nycomed related to the Preatact agreement are as follows (in thousands):

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2010	2009	2010	2009
Royalties	\$ 2,054	\$ 2,416	\$ 4,428	\$ 4,479
Product sales	-	-	453	-
Milestone and license fees	-	2,203	-	2,203
Total revenues	<u>\$ 2,054</u>	<u>\$ 4,619</u>	<u>\$ 4,881</u>	<u>\$ 6,682</u>

(6) Comprehensive Income (Loss)

The components of the Company's comprehensive income (loss) are as follows, in thousands:

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2010	2009	2010	2009
Other comprehensive income (loss):				
Gross unrealized (loss) gain on marketable investment securities during the period	\$ (46)	\$ 1,795	\$ (81)	\$ (628)
Reclassification for recognized (gain) loss on marketable investment securities during the period	-	(22)	(2,780)	2,182
Net unrealized (loss) gain on marketable investment securities	(46)	1,773	(2,861)	1,554
Foreign currency translation (loss) gain	(12)	9	(1)	48
Net (loss) income	(6,301)	2,617	(9,353)	(8,119)
Comprehensive (loss) income	<u>\$ (6,359)</u>	<u>\$ 4,399</u>	<u>\$ (12,215)</u>	<u>\$ (6,517)</u>

(7) Long-term Debt

The following table reflects the carrying value of the Company's long-term debt under various financing arrangements as of June 30, 2010 and December 31, 2009 (in thousands):

	June 30, 2010	December 31, 2009
Convertible notes	\$ 50,000	\$ 50,000
Non-recourse debt	287,823	288,694
Capital lease obligation	-	14
Total debt	337,823	338,708
Less current position	27,827	48,514
Total long-term debt	<u>\$ 309,996</u>	<u>\$ 290,194</u>

(a) Convertible Notes

In August 2007, the Company completed a private placement of \$50.0 million in 5.75% Convertible Notes due August 7, 2014 (5.75% Convertible Notes). The Company received net proceeds from the 5.75% Convertible Notes of approximately \$49.4 million, after deducting costs associated with the offering. The 5.75% Convertible Notes accrue interest at an annual rate of 5.75% payable quarterly in arrears on the first day of the succeeding calendar quarter commencing January 1, 2008. Accrued interest on the 5.75% Convertible Notes was \$0 as of June 30, 2010 and December 31, 2009. The holders may convert all or a portion of the 5.75% Convertible Notes into common stock at any time, subject to certain limitations, on or before August 7, 2014. The 5.75% Convertible Notes are convertible into common stock at a conversion price of \$5.44 per share, subject to adjustments in certain events. The 5.75% Convertible Notes are unsecured debt obligations and rank equally in right of payment with all existing and future unsecured senior indebtedness. On or after August 7, 2012, the Company may redeem any or all of the 5.75% Convertible Notes at a redemption price of 100% of their principal amount, plus accrued and unpaid interest to the day preceding the redemption date. The 5.75% Convertible Notes provide for certain events of default, including payment defaults, breaches of covenants and certain events of bankruptcy, insolvency and reorganization. The 5.75% Convertible Notes also provide that if there shall occur a fundamental change, as

defined, at any time prior to the maturity of the Note, then the holder shall have the right, at the Holder's option, to require the Company to redeem the notes, or any portion thereof plus accrued interest and liquidated damages, if any. If a change of control, as defined, occurs and if the holder converts notes in connection with any such transaction, the Company will pay a make whole premium by increasing the conversion rate applicable to the notes. If any event of default occurs and is continuing, the principal amount of the 5.75% Convertible Notes, plus accrued and unpaid interest, if any, may be declared immediately due and payable. The Company has filed a registration statement with the SEC, which has been declared effective, covering the common stock issuable upon conversion of the 5.75% Convertible Notes. The Company incurred debt issuance costs of approximately \$600,000, which have been deferred and which are being amortized over a seven-year period. The effective interest rate on the 5.75% Convertible Notes, including debt issuance costs, is 5.9%.

Pursuant to the Registration Rights Agreement, the Company has filed a shelf registration statement with the SEC, covering resales of the common stock issuable upon conversion of the 5.75% Convertible Notes. The registration statement has been declared effective. The Company agreed to use its reasonable best efforts to keep the registration statement effective until the earlier of (i) the date as of which holders may sell all of the securities covered by the registration statement without restriction pursuant to Rule 144(k) promulgated under the Securities Act of 1933 or (ii) the date on which holders shall have sold all of the securities covered by the registration statement. If the Company fails to comply with these covenants or suspends use of the registration statement for periods of time that exceed what is permitted under the Registration Rights Agreement, the Company is required to pay liquidated damages in an amount equivalent to 1% per annum of (a) the principal amount of the notes outstanding, or (b) the conversion price of each underlying share of common stock that has been issued upon conversion of a note, in each case, until the Company is in compliance with these covenants. The Company believes the likelihood of such an event occurring is remote and, as such, the Company has not recorded a liability as of June 30, 2010.

(b) Non-recourse Debt

Sensipar and Mimpara-Secured Non-recourse Debt

In December 2004, the Company completed a private placement of \$175.0 million in Class A Notes. The Company received net proceeds from the issuance of the Class A Notes of approximately \$169.3 million, after deducting costs associated with the offering. The Class A Notes accrue interest at an annual rate of 8.0% payable quarterly in arrears on March 30, June 30, September 30 and December 30 of each year (Payment Date). The Class A Notes are secured by certain royalty and related rights of the Company under its agreement with Amgen, Inc., for Sensipar® and Mimpara® (cinacalcet HC1). Additionally, the only source for interest payments and principal repayment of the Class A Notes is limited to royalty and milestone payments received from Amgen. The Class A Notes are non-recourse to NPS Pharmaceuticals, Inc. Payments of principal will be made on March 30 of each year commencing March 30, 2006, to the extent there is sufficient cash available for such principal payment. As of June 30, 2010 and December 31, 2009, the outstanding principal balance on the Class A Notes was \$46.2 million and \$94.7 million, respectively. In the event the Company receives royalty and milestone payments under its agreement with Amgen above certain specified amounts for a given year, an annual redemption premium on principal repayment will be owed. The redemption premium ranges from 0% to 41.5% of principal payments, depending on the annual net sales of cinacalcet HC1 by Amgen. As of June 30, 2010 and December 31, 2009, the Company classified \$27.8 million and \$48.5 million, respectively, of the Class A Notes as current based on royalty and milestone payments accrued during the six months ended June 30, 2010 and the year ended December 31, 2009, respectively, plus other available balances in the restricted cash reserve account less estimated redemption premiums. The Company may repurchase, in whole but not in part, the Class A Notes on any Payment Date at a premium ranging from 0% to 41.5% of outstanding principal, depending on the preceding four quarters' sales of cinacalcet HC1 by Amgen. The Company is accruing the estimated redemption premiums over the estimated life of the debt using the effective interest method. Full repayment of the Class A Notes is estimated to occur in 2011. The estimated life is based on projections of royalties to be earned from cinacalcet HC1 sales. Accrued interest on the Class A Notes was approximately \$10.9 million and \$17.9 million as of June 30, 2010 and December 31, 2009, respectively, which includes the Company's estimate of the redemption premium. The Company incurred debt issuance costs of \$5.7 million, which are also being amortized using the effective interest method. The current effective interest rate on the Class A Notes, including debt issuance costs and estimated redemption premiums, is approximately 9.6%.

In August 2007, the Company completed a private placement of \$100.0 million in non-recourse 15.5% Notes due March 30, 2017 (Class B Notes). The Company received net proceeds from the issuance of the Class B Notes of approximately \$97.0 million, after deducting costs associated with the offering. The Class B Notes accrue

interest at an annual rate of 15.5% payable quarterly in arrears on March 30, June 30, September 30 and December 30 of each year. The Class B Notes are secured by certain royalty and related rights of the Company under its agreement with Amgen, for Sensipar and Mimpara (cinacalcet HCl). Additionally, the only source for interest payments and principal repayment of the Class B Notes is limited to royalty and milestone payments received from Amgen and only after the Class A Notes are paid in full. Prior to repayment in full of the Class A Notes, interest on the Class B Notes will be paid in kind through the issuance of notes (the PIK Notes) which will be part of the same class and have the same terms and rights as the Class B Notes, except that interest on the PIK Notes will begin to accrue from the date that such PIK Notes are issued. The aggregate principal amount of the outstanding Class B Notes will continue to increase until the Class A Notes are paid in full. The Class B Notes are non-recourse to NPS Pharmaceuticals, Inc. The Company may repurchase, in whole but not in part, the Class B Notes at a calculated Redemption Price based on the timing of repurchase and the source of proceeds for the repurchase. The Redemption Price varies between 100.0% and 107.75% depending on these variables. As of June 30, 2010 and December 31, 2009, the outstanding principal balances on the Class B Notes, were \$155.4 million and \$144.0 million, which included PIK Notes of \$55.4 million and \$44.0 million, respectively. The Company incurred debt issuance costs of \$3.6 million, which are being amortized using the effective interest method. The effective interest rate on the Class B Notes, including debt issuance costs, is approximately 16.0%.

Under the Company's agreements for the Class A Notes and Class B Notes, the Company would potentially be liable for its breaches or defaults, if any.

Preotact-Secured Non-recourse Debt

In July 2007, the Company entered into an agreement with DRI Capital, or DRI, formerly Drug Royalty L.P.3, in which the Company sold to DRI its right to receive future royalty payments arising from sales of Preotact under its license agreement with Nycomed. Under the agreement, DRI paid the Company an up-front purchase price of \$50.0 million. If and when DRI receives two and a half times the amount paid to the Company, the agreement will terminate and the remainder of the royalties, if any, will revert back to the Company. In connection with the Company's July 2007 agreement with DRI, the Company granted DRI a security interest in its license agreement with Nycomed for Preotact and certain of its patents and other intellectual property underlying that agreement. In the event of a default by NPS under the agreement with DRI, DRI would be entitled to enforce its security interest against NPS and the property described above. The Company has determined that it should classify the initial up-front purchase price as debt which should be amortized using the effective interest method over the estimated life of approximately 9 years. The liability recorded related to the DRI transaction was \$50.0 million as of June 30, 2010 and December 31, 2009, and accrued interest under the DRI agreement was \$2.3 million and \$3.8 million as of June 30, 2010 and December 31, 2009, respectively. Through June 30, 2010, \$24.5 million has been paid to DRI. The repayment of the \$50.0 million is secured solely by future royalty payments arising from sales of Preotact by Nycomed. The effective interest rate under the agreement, including issuance costs, is approximately 12.7%.

REGPARA-Secured Non-recourse Debt

In February 2010, the Company entered into an agreement with an affiliate of DRI Capital, or DRI, in which the Company sold to DRI its right to receive future royalty payments arising from sales of REGPARA[®] (cinacalcet HCl) under its license agreement with Kyowa Hakko Kirin. Under the agreement, DRI paid the Company an up-front purchase price of \$38.4 million. If and when DRI receives two and a half times the amount paid to the Company, the agreement will terminate and the remainder of the royalties, if any, will revert back to the Company. In connection with the Company's March 2010 agreement with DRI, the Company granted DRI a security interest in its license agreement with Kyowa Hakko Kirin for REGPARA and certain of its patents and other intellectual property underlying that agreement. In the event of a default by NPS under the agreement with DRI, DRI would be entitled to enforce its security interest against NPS and the property described above. The Company has determined that it should classify the initial up-front purchase price as debt which should be amortized using the effective interest method over the estimated life of approximately 11 years. In accordance with the agreement, on March 1, 2010, DRI received the \$2.1 million royalty owed to NPS for REGPARA sales during the six months ended December 31, 2009, which reduced the liability recorded for the DRI transaction to \$36.3 million as of June 30, 2010. Accrued interest under the DRI agreement was \$2.2 million as of June 30, 2010. Through June 30, 2010, \$2.1 million has been paid to DRI. The repayment of the remaining \$36.3 million is secured solely by future royalty payments arising from sales of REGPARA by Kyowa Hakko Kirin. The effective interest rate under the agreement, including issuance costs, is approximately 18.2%.

(8) Income Taxes

The Company accounts for penalties or interest related to uncertain tax positions as part of its provision for income taxes. Due to the Company's net operating loss carryforwards, any adjustment related to a liability would not be expected to result in a cash tax liability. Accordingly, the Company has not accrued for penalties or interest for both the U.S. (both Federal and state) and Canada as of June 30, 2010 and December 31, 2009. Assuming the continued existence of a full valuation allowance on the Company's net deferred tax assets, future recognition of any of the Company's unrecognized tax benefits would not impact the effective tax rate.

The Company files income tax returns in various jurisdictions with varying statutes of limitations. The statute of limitations for income tax audits in the U.S. remains open for the tax years ended on or after December 31, 2004.

The Company recorded income tax benefit of \$0 and \$1.0 million for the three and six months ended June 30, 2009 primarily for the Company's recognition of income tax credits from the Canadian province of Quebec relating to research and development activities for which the statute of limitations expired.

(9) Commitments and Contingencies

The Company has agreed to indemnify, under certain circumstances, certain manufacturers and service providers from and against any and all losses, claims, damages or liabilities arising from services provided by such manufacturers and service providers or from any use, including clinical trials, or sale by the Company or any Company agent of any product supplied by the manufacturers. The Company has entered into long-term agreements with various third-party contract manufacturers for the production and packaging of the active pharmaceutical ingredient and drug product. Under the terms of these various contracts, the Company may be required to purchase certain minimum quantities of product each year.

(10) Legal Proceedings

Sensipar® (cinacalcet HCl) Patent Infringement Litigation

On June 16, 2008, the Company reported the receipt of Paragraph IV Certification Notice Letters ("Notice Letters") related to Abbreviated New Drug Applications (ANDA) submitted to the U.S. Food and Drug Administration ("FDA") by Barr Laboratories Inc. ("Barr") and Teva Pharmaceuticals USA, Inc. ("Teva U.S.") requesting approval to market and sell generic versions of Sensipar (cinacalcet HCl). The Notice Letters alleged that the U.S. Patent Numbers 6,011,068 ("the '068 patent"), 6,031,003 ("the '003 patent"), 6,313,146 ("the '146 patent"), and 6,211,244 ("the '244 patent") covering Sensipar are invalid, unenforceable and/or will not be infringed by the manufacture, use or sale of the product described in the ANDAs.

Under the Company's licensing agreement with Amgen, Amgen is responsible for all development and commercial activities involving Sensipar, as well as enforcing applicable patent rights, in the licensed territories. The '068 patent, the '003 patent and the '146 patent are co-owned by the Company and The Brigham and Women's Hospital, which licensed its rights to the Company. The Company has licensed rights to these patents and the '244 patent to Amgen. On July 25, 2008, The Brigham and Women's Hospital, Amgen and the Company ("the Plaintiffs") filed a patent infringement action in United States District Court, District of Delaware, No. 1:08cv00464 HB, against Barr, Teva U.S. and Teva Pharmaceutical Industries Ltd ("Teva Israel" and collectively with Teva U.S., "Teva") relating to each of the patents referenced above. On August 18, 2008, Barr and Teva filed answers, defenses, and counterclaims alleging that the '068, '003, '146, and '244 are invalid and/or not infringed. On September 10, 2008, the Company, The Brigham and Women's Hospital and Amgen filed answers to Barr's and Teva's counterclaims. On April 3, 2009, Barr and Teva filed motions to amend their answers, defenses, and counterclaims to include allegations that the Sensipar patents are unenforceable for inequitable conduct. Teva also sought to add a counterclaim asserting that Amgen infringed Teva's U.S. Patent No. 7,449,603. On May 15, 2009, the Court denied the motion to add the counterclaim against Amgen but granted motions by Teva and Barr to add counterclaims of unenforceability for inequitable conduct. On September 24, 2009, the Court granted a motion brought by Teva and Barr to proceed on representative claims. The trial in the first instance shall be on the representative claims selected by the Plaintiffs (no more than 12) without prejudice to a trial at a later point if Plaintiffs request on any remaining claims. A revised scheduling order issued by the Court requires discovery to be completed by October 29, 2010, but does not establish a trial date. By statute, since plaintiffs initiated a patent infringement lawsuit against Barr and Teva within 45 days of receipt of the Notice Letters, the FDA is automatically precluded from approving the ANDAs until the earlier of September 8, 2011 or a district court decision finding the

patents invalid, unenforceable or not infringed. The Company is confident of the validity and enforceability of these patents and in conjunction with The Brigham and Women's Hospital and Amgen is vigorously prosecuting these actions to protect these patents from infringement.

On May 20, 2009, Teva filed a lawsuit in federal court in the Eastern District of Pennsylvania against Amgen alleging that certain processes used by Amgen to manufacture Sensipar (cinacalcet HCl) infringe Teva's U.S. Patent No. 7,449,603. Teva is seeking declaratory relief and damages in an unspecified amount. Pursuant to the Company's license agreement with Amgen, so long as a patent infringement proceeding by a third-party against Amgen continues for the manufacture, use or sale of cinacalcet HCl in any country, Amgen may reserve up to fifty percent of the royalties otherwise payable to the Company with respect to cinacalcet HCl sales in the country in question until the proceeding is concluded. If Teva's patent is determined to be un infringed, unenforceable or invalid, Amgen is required to promptly pay any reserved royalties to the Company. If Teva's patent is held to be valid and infringed, or if Amgen enters into a settlement of Teva's infringement claim, then Amgen may deduct any damages or settlement amount with respect to such claim from the reserved royalties prior to payment of any remaining amount. In the event any damages and/or settlement amounts exceed the amount of reserved royalties, Amgen could withhold such excess from its future royalty obligations in that country. Amgen has notified the Company that it is not reserving any of the 2010 second quarter's cinacalcet HCl royalties payable to the Company and has not previously reserved any cinacalcet HCl royalties payable to the Company. Amgen filed a motion to dismiss the complaint, in part, based on Amgen's claim that the Court lacks subject matter jurisdiction over Teva U.S. On July 22, 2009, an amended complaint was filed by Teva Israel against Amgen. Teva U.S. is not named as a plaintiff in the amended complaint.

(11) Stock Options and Employee Stock Purchase Plan

During the six months ended June 30, 2010, the Company's Board of Directors awarded a total of 1,130,700 performance condition options to certain of the Company's employees. Vesting of these options are subject to the Company achieving certain performance criteria established at the grant date and the individuals fulfilling a service condition (continued employment).

The Company utilized the Black-Scholes option pricing model to determine the grant date fair value of the awards. As of June 30, 2010, the Company does not believe that the achievement of the performance criteria is probable and therefore, has not recognized any compensation expense related to these options during the three and six months ended June 30, 2010. Compensation expense will be recognized only once the performance condition is probable of being achieved and then only the cumulative amount related to the service condition that has been fulfilled.

On May 19, 2010, the shareholders approved an Employee Stock Purchase Plan whereby qualified employees are allowed to purchase limited amounts of the Company's common stock at the lesser of 85% of the market price at the beginning or end of the offering period. The shareholders have authorized 500,000 shares for purchase by employees.

(12) Capital Stock

In April 2010, the Company completed a public sale of 10,350,000 shares of its common stock at a per share price of \$5.50. Net proceeds to the Company from the sale totaled approximately \$53.2 million, after deducting expenses and the commission in connection with the offering paid by the Company.

(13) Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position, results of operations or disclosures upon adoption.

In April 2010, the FASB issued ASU 2010-17, *Revenue Recognition – Milestone Method (Topic 605): Milestone Method of Revenue Recognition* ("ASU 2010-17"). ASU 2010-17 provides guidance on applying the milestone method to milestone payments for achieving specified performance measures when those payments are related to uncertain future events. Under the Consensus, entities can make an accounting policy election to recognize arrangement consideration received for achieving specified performance measures during the period in which the milestones are achieved, provided certain criteria are met for the milestones to be considered substantive.

This ASU is effective on a prospective basis for research and development milestones achieved in fiscal years, beginning on or after June 15, 2010, which for NPS means 2011. Early adoption is permitted; however, adoption of this guidance as of a date other than January 1, 2011 will require the Company to apply this guidance retrospectively effective as of January 1, 2010 and will require disclosure of the effect of this guidance as applied to all previously reported interim periods in the fiscal year of adoption. As the Company plans to implement ASU No. 2010-17 prospectively, the effect of this guidance will be limited to future transactions. The impact of this ASU is not expected to be material to the consolidated financial statements of the Company.

In October 2009, the FASB issued ASU 2009-13, *Multiple-Deliverable Revenue Arrangements*, (“ASU 2009-13”). ASU 2009-13, amends existing revenue recognition accounting pronouncements that are currently within the scope of ASC Subtopic 605-25 (previously included within EITF Issue No. 00-21, Revenue Arrangements with Multiple Deliverables). ASU 2009-13 provides accounting principles and application guidance on how the arrangement should be separated, and the consideration allocated. This guidance changes how to determine the fair value of undelivered products and services for separate revenue recognition. Allocation of consideration is now based upon management’s estimate of the selling price for an undelivered item when there is no other means to determine the fair value of that undelivered item. This new guidance is effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010.

In June 2009, the FASB issued ASU 2009-17, *Improvements to Financial Reporting by Enterprises Involved with Variable Interest Entities* (“ASU 2009-17”). ASU 2009-17 amends previously issued accounting guidance for the consolidation of variable interest entities to require an enterprise to determine whether its variable interest or interests give it a controlling financial interest in a variable interest entity. The primary beneficiary of a variable interest entity is the enterprise that has both (1) the power to direct the activities of a variable interest entity that most significantly impact the entity’s economic performance and (2) the obligation to absorb losses of the entity that could potentially be significant to the variable interest entity or the right to receive benefits from the entity that could potentially be significant to the variable interest entity. The new standard also amends existing literature to require ongoing reassessments of whether an enterprise is the primary beneficiary of a variable interest entity. The Company adopted ASU 2009-17 on January 1, 2010. The adoption of ASU 2009-17 did not have a material impact on the Company’s financial position or results of operations.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Cautionary Statement Regarding Forward-Looking Statements

The following discussion and analysis is provided to further the reader's understanding of the condensed consolidated financial statements, financial condition and results of operations of NPS in this Quarterly Report on Form 10-Q. This discussion should be read in conjunction with the Consolidated Financial Statements and the accompanying notes included in our filings with the SEC, including our 2009 Annual Report on Form 10-K.

This Quarterly Report on Form 10-Q contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our management’s judgment regarding future events. In many cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “plan,” “expect,” “anticipate,” “estimate,” “predict,” “intend,” “potential” or “continue” or the negative of these terms or other words of similar import, although some forward-looking statements are expressed differently. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q and the documents incorporated by reference into this report regarding our financial position, business strategy and plans or objectives for future operations are forward-looking statements. Without limiting the broader description of forward-looking statements above, we specifically note that statements regarding potential drug candidates, their potential therapeutic effect, the possibility of obtaining regulatory approval, our ability or the ability of our collaborators to manufacture and sell any products, market acceptance, or our ability to earn a profit from sales or licenses of any drug candidate are all forward-looking in nature. We cannot guarantee the accuracy of the forward-looking statements, and you should be aware that results and events could differ materially and adversely from those contained in the forward-looking statements due to a number of factors, including:

- Our ability to effectively outsource activities critical to the advancement of our product candidates and manage those companies to whom such activities are outsourced;
- our and our collaborators’ ability to successfully complete clinical trials, receive required regulatory approvals and the length, time and cost of obtaining such regulatory approvals and commercialize products;

- our ability to secure additional funds;
- the successful continuation of our strategic collaborations or changes in our relationships with our collaborators;
- competitive factors;
- our ability to maintain the level of our expenses consistent with our internal budgets and forecasts;
- the ability of our contract manufacturers to successfully produce adequate supplies of our product candidates and drug delivery devices to meet clinical trial and commercial launch requirements;
- variability of our royalty, license and other revenues;
- our ability to enter into and maintain agreements with current and future collaborators on commercially reasonable terms;
- the demand for securities of pharmaceutical and biotechnology companies in general and our common stock in particular;
- uncertainty regarding our patents and patent rights;
- compliance with current or prospective governmental regulation;
- technological change; and
- general economic and market conditions.

You should also consider carefully the statements set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009 entitled “Risk Factors” which address these and additional factors that could cause results or events to differ materially from those set forth in the forward-looking statements. All subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the applicable cautionary statements. In addition, new risks emerge from time to time and it is not possible for management to predict all such risk factors or to assess the impact of such risk factors on our business. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update or revise these forward-looking statements.

Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to all such reports are available, free of charge, on our Internet website under “Investors—SEC Filings,” as soon as reasonably practicable after we file electronically such reports with, or furnish such reports to, the SEC. Our Internet website address is <http://www.npsp.com>. Information on our website does not constitute a part of this Quarterly Report on Form 10-Q.

Overview

We are a biopharmaceutical company focused on the development of new treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs. Our lead clinical programs involve two proprietary therapeutic proteins to restore or replace biological function: teduglutide and NPSP558 (recombinant parathyroid hormone 1-84 or rhPTH 1-84). Teduglutide is our analog of GLP-2, a peptide involved in the regeneration and repair of the intestinal lining, and is in Phase 3 clinical development for short bowel syndrome (“SBS”). SBS is a highly disabling condition that results from surgical resection, congenital defect or disease-associated loss of absorption and the subsequent inability to maintain fluid, electrolyte, and nutrient balances on a conventional diet. NPSP558 is our recombinant full-length human parathyroid hormone (“rhPTH (1-84)”) that is in Phase 3 clinical development for hypoparathyroidism, a rare condition in which the body does not maintain normal calcium levels in the blood due to insufficient levels of parathyroid hormone.

We have incurred cumulative losses from inception through June 30, 2010 of approximately \$932.1 million. We expect to continue to incur significant operating losses over at least the next several years as we continue our current and anticipated development projects. Activities that will increase our future operating losses include current and future clinical trials with teduglutide and NPSP558; activities to obtain FDA approval to market teduglutide and NPSP558 in the U.S.; and manufacturing and commercial-readiness costs for teduglutide and NPSP558 in the U.S.

Results of Operations

Three Months Ended June 30, 2010 and 2009

The following table summarizes selected operating statement data for the three months ended June 30, 2010 and 2009 (amounts in thousands):

	Three Months Ended June 30,	
	2010	2009
Revenues:		
Royalties	\$ 23,969	\$ 22,827
Product sales	50	8
Milestones and license fees	-	2,814
Total revenues	\$ 24,019	\$ 25,649
Operating expenses:		
Cost of license fees	\$ -	\$ 123
% of milestones and license fees	- %	4 %
Research and development	\$ 15,799	\$ 6,427
% of total revenue	66 %	25 %
General and administrative	\$ 4,193	\$ 4,981
% of total revenue	17 %	19 %

Revenues. Substantially all our revenues are from royalties, license fees, milestone payments and product sales from our licensees and collaborators. These revenues fluctuate from quarter to quarter. Our revenues were \$24.0 million for the quarter ended June 30, 2010 compared to \$25.6 million for the quarter ended June 30, 2009. We recognized revenue under our research and license agreements during the three months ended June 30, 2010 and 2009, respectively, as follows (amounts in thousands):

	Three Months Ended June 30,	
	2010	2009
Royalties:		
Sensipar and Mimpara (cinacalcet HCl)	\$ 20,290	\$ 19,359
Preotact (parathyroid hormone (PTH 1-84))	2,054	2,416
Regpara (cinacalcet HCl)	1,338	885
Nucynta (tapentadol)	287	167
Total royalties	23,969	22,827
Product sales	50	8
Milestones and license fees:		
Preotact	-	2,203
Teduglutide	-	624
Other	-	(13)
Total milestones and license fees	-	2,814
Total revenues	\$ 24,019	\$ 25,649

The increase in royalty revenue earned from Amgen's sales of Sensipar and Mimpara (cinacalcet HCl) for the three months ended June 30, 2010 was primarily due to demand. Amgen pays royalties on sales of Sensipar and Mimpara directly to a wholly owned subsidiary of NPS and the royalties are used to repay non-recourse debt issued in August 2007 and December 2004, therefore we do not receive any such royalty payments.

For the three months ended June 30, 2010 and 2009, our revenues related to our agreement with Nycomed for Preotact were \$2.1 million and \$2.4 million in royalty revenue, respectively, and \$0 and \$2.2 million in milestone revenue, respectively. Changes in foreign exchange negatively impacted royalty revenue earned from Nycomed's

sales of Preotact in the three months ended June 30, 2010. Excluding the negative impact of foreign exchange, Preotact royalty revenue would have remained flat compared to the three months ended June 30, 2009. The milestone earned in the three months ended June 30, 2009 relates to achieving a certain cumulative sales threshold during the quarter. In July 2007, we sold our right to receive certain future royalty payments from Nycomed's sale of Preotact in Europe to DRI Capital ("DRI"), therefore we do not receive any such royalty payments.

During the three months ended June 30, 2010 and 2009, we recognized royalty revenue of \$1.3 million and \$885,000, respectively, from Kyowa Hakko Kirin for sales of REGPARA. In February 2010, we sold our right to receive certain future royalty payments from Kyowa Hakko Kirin's sale of REGPARA to an affiliate of DRI; therefore, we do not receive any such royalty payments.

During the three months ended June 30, 2010 and 2009, we recognized royalty revenue of \$287,000 and \$167,000, respectively, from Ortho-McNeil Pharmaceutical, Inc. ("Ortho") for sales of Nucynta, which was launched in the second quarter of 2009.

For the three months ended June 30, 2010 and 2009, our revenues related to our agreement with Nycomed for teduglutide were \$0 and \$632,000, respectively. In September 2007, we entered into an agreement with Nycomed that allows Nycomed to develop and commercialize teduglutide in territories outside of North America for gastrointestinal disorders. In connection with this agreement, we received a \$35.0 million up-front license fee. Due to our continued involvement under the agreement we deferred recognition of this payment and recognized revenue over the estimated performance period including \$0 and \$624,000 for the three months ended June 30, 2010 and 2009, respectively. The performance period ended on May 4, 2009 and therefore, the up-front license fee has been fully recognized as revenue as of June 30, 2009.

Cost of License Fees. Our cost of license fees primarily relates to fees owed to a third-party resulting from the licensing of teduglutide to Nycomed in September 2007. We recorded cost of license fees of \$0 and \$123,000 during the three months ended June 30, 2010 and 2009, respectively. Under the third-party licensing agreement, we made cash payments of approximately \$6.6 million, and we incurred additional costs of \$591,000 related to the Nycomed teduglutide agreement, both in 2007. These costs were deferred and amortized over the same period and in the same manner as the related deferred revenue. All of the deferred cost of license fees have been recognized as expense as of June 30, 2009 in conjunction with the related deferred revenue.

Research and Development. Our research and development expenses are primarily comprised of the fees paid and costs reimbursed to outside professionals to conduct research, preclinical and clinical trials, and to manufacture drug compounds and related supplies prior to FDA approval, as well as personnel-related costs for our employees who are dedicated to development activities. For the three months ended June 30, 2010, our research and development expenses increased to \$15.8 million from \$6.4 million for the three months ended June 30, 2009. The increase in research and development expenses primarily related to a \$8.9 million increase in outside services principally due to higher levels of activity in our ongoing clinical studies and the production of commercial-scale batches, and a \$506,000 increase in personnel and related costs primarily due to the advancement of our registration programs for teduglutide and NPSP558.

General and Administrative. Our general and administrative expenses consist primarily of professional fees, the costs of our management and administrative staff and administrative expenses. Our general and administrative expenses decreased to \$4.2 million for the three months ended June 30, 2010 from \$5.0 million for the three months ended June 30, 2009. The reduction in general and administrative expenses primarily related to a \$598,000 decrease in outside legal costs and other administrative costs for the three months ended June 30, 2010.

Interest Income. Interest income decreased to \$89,000 for the three months ended June 30, 2010 from \$400,000 from the comparative period in 2009, primarily due to lower interest rates on our investments.

Interest Expense. Our interest expense for the three months ended June 30, 2010 decreased to \$11.2 million compared to \$11.8 million for the three months ended June 30, 2009. Our long-term royalty forecasts for Sensipar and Mimpara, Preotact and REGPARA are used in conjunction with the calculation of interest expense related to our non-recourse debt. Interest expense decreased slightly primarily due to decreased interest expense on the Class A Notes resulting from a decrease in the forecast of Sensipar and Mimpara royalties (\$1.7 million) and a \$48.5 million principal payment in March 2010 (\$970,000) and (ii) non-recourse debt associated with our Preotact royalties (\$397,000) due to a decrease in the forecast of Preotact royalties. These decreases in interest expense were partially offset by (i) non-recourse debt associated with the sale of certain of our REGPARA royalty rights in February 2010

(\$1.7 million) and (ii) Class B Notes (\$850,000) due to an increased balance on the notes due to the issuance of paid-in-kind notes for interest accrued.

Six Months Ended June 30, 2010 and 2009

The following table summarizes selected operating statement data for the six months ended June 30, 2010 and 2009 (amounts in thousands):

	Six Months Ended June 30,	
	2010	2009
Revenues:		
Royalties	\$ 41,758	\$ 37,235
Product sales	534	8
Milestones and license fees	2,025	4,735
Total revenues	\$ 44,317	\$ 41,978
Operating expenses:		
Cost of license fees	\$ 6	\$ 481
% of milestones and license fees	0 %	10 %
Research and development	\$ 25,307	\$ 12,259
% of total revenue	57 %	29 %
General and administrative	\$ 8,490	\$ 9,534
% of total revenue	19 %	23 %

Revenues. Our revenues were \$44.3 million for the six months ended June 30, 2010 compared to \$42.0 million for the six months ended June 30, 2009. We recognized revenue under our research and license agreements during the six months ended June 30, 2010 and 2009, respectively, as follows (amounts in thousands):

	Six Months Ended June 30,	
	2010	2009
Royalties:		
Sensipar and Mimpara (cinacalcet HCl)	\$ 34,364	\$ 31,003
Preotact (parathyroid hormone (PTH 1-84))	4,428	4,479
Regpara (cinacalcet HCl)	2,456	1,584
Nucynta (tapentadol)	509	167
Other	1	2
Total royalties	41,758	37,235
Product sales	534	8
Milestones and license fees:		
Sensipar and Mimpara	2,000	-
Preotact	-	2,203
Teduglutide	-	2,494
Other	25	38
Total milestones and license fees	2,025	4,735
Total revenues	\$ 44,317	\$ 41,978

The increase in royalty revenue earned from Amgen's sales of Sensipar and Mimpara (cinacalcet HCl) for the six months ended June 30, 2010 was primarily due to demand. The \$2.0 million milestone revenue earned from Amgen during the six months ended June 30, 2010 was for their initiation of a Phase 3 study of Sensipar in primary hyperparathyroidism in March 2010.

For the six months ended June 30, 2010 and 2009, our revenues related to our agreement with Nycomed for Preotact were \$4.4 million and \$4.5 million in royalty revenue, respectively, and \$0 and \$2.2 million in milestone revenue, respectively. Changes in foreign exchange negatively impacted royalty revenue earned from Nycomed's sales of Preotact in the six months ended June 30, 2010. Excluding the negative impact of foreign exchange, Preotact royalty revenue would have increased 8% compared to the six months ended June 30, 2009. The milestone earned in the six months ended June 30, 2009 relates to achieving a certain cumulative sales threshold during the year.

During the six months ended June 30, 2010 and 2009, we recognized royalty revenue of \$2.5 million and \$1.6 million, respectively, from Kyowa Hakko Kirin for sales of REGPARA, which was launched in the first quarter of 2008. In February 2010, we sold our right to receive certain future royalty payments from Kyowa Hakko Kirin's sale of REGPARA to an affiliate of DRI. The agreement provides DRI with the right to receive payments related to sales of REGPARA occurring on or after July 1, 2009, and in March 2010, DRI received the \$2.1 million receivable from Kyowa Hakko Kirin that we recorded at December 31, 2009, which related to sales during the six months ended December 31, 2009.

During the six months ended June 30, 2010 and 2009, we recognized royalty revenue of \$509,000 and \$167,000, respectively, from Ortho for sales of Nucynta, which was launched in the second quarter of 2009.

For the six months ended June 30, 2010 and 2009, our revenues related to our agreement with Nycomed for teduglutide were \$0 and \$2.5 million, respectively. In September 2007, we entered into an agreement with Nycomed that allows Nycomed to develop and commercialize teduglutide in territories outside of North America for gastrointestinal disorders. In connection with this agreement, we received a \$35.0 million up-front license fee. Due to our continued involvement under the agreement we deferred recognition of this payment and recognized revenue over the estimated performance period including \$0 and \$2.5 million for the six months ended June 30, 2010 and 2009, respectively. The performance period ended on May 4, 2009 and therefore, the up-front license fee has been fully recognized as revenue as of June 30, 2009.

Cost of License Fees. Our cost of license fees primarily relate to fees owed to a third-party resulting from the licensing of teduglutide to Nycomed in September 2007. We recorded cost of license fees of \$6,000 and \$481,000 during the six months ended June 30, 2010 and 2009, respectively. Under the third-party licensing agreement, we made cash payments of approximately \$6.6 million, and we incurred additional costs of \$591,000 related to the Nycomed teduglutide agreement, both in 2007. These costs were deferred and amortized over the same period and in the same manner as the related deferred revenue. All of the deferred cost of license fees have been recognized as expense as of June 30, 2009 in conjunction with the related deferred revenue.

Research and Development. Our research and development expenses are primarily comprised of the fees paid and costs reimbursed to outside professionals to conduct research, preclinical and clinical trials, and to manufacture drug compounds and related supplies prior to FDA approval, as well as personnel-related costs for our employees who are dedicated to development activities. For the six months ended June 30, 2010, our research and development expenses increased to \$25.3 million from \$12.3 million for the six months ended June 30, 2009. The increase in research and development expenses primarily related to a \$12.0 million increase in outside services principally due to higher levels of activity in our ongoing clinical studies, and the production of validation and commercial-scale batches, and a \$1.1 million increase in personnel and related costs primarily due to the advancement of our registration programs for teduglutide and NPSP558.

General and Administrative. Our general and administrative expenses consist primarily of professional fees, the costs of our management and administrative staff and administrative expenses. Our general and administrative expenses decreased to \$8.5 million for the six months ended June 30, 2010 from \$9.5 million for the six months ended June 30, 2009. The reduction in general and administrative expenses primarily related to a \$940,000 decrease in outside legal costs and other administrative costs for the six months ended June 30, 2010.

Interest Income. Interest income decreased to \$239,000 for the six months ended June 30, 2010 from \$1.0 million from the comparative period in 2009, primarily due to lower interest rates on our investments.

Interest Expense. Our interest expense decreased to \$24.5 million for the six months ended June 30, 2010 from \$27.5 million for the comparable period in 2009. Our long-term royalty forecasts for Sensipar and Mimpara, Preotact and REGPARA are used in conjunction with the calculation of interest expense related to our non-recourse debt. The decrease in interest expense is due primarily to a lower effective interest rate related to the Class A Notes resulting from a decrease in the forecast of Sensipar and Mimpara royalties (\$5.4 million) and a \$48.5 million

principal payment in March 2010 and a \$35.3 million principal payment in April 2009 (\$1.7 million) partially offset by increased interest expense on the (i) Class B Notes (\$1.7 million) due to an increased balance on the notes due to the issuance of paid-in-kind notes for interest accrued, (ii) non-recourse debt associated with the sale of certain of our REGPARA royalty rights in February 2010 (\$2.2 million) and (iii) non-recourse debt associated with our Preotact royalties (\$371,000) due to an increase in the forecast of Preotact royalties.

Gain on Sale of Marketable Investment Securities. We recorded a gain on sale of marketable investment securities of \$3.8 million and \$0 for the six months ended June 30, 2010 and 2009, respectively, related primarily to the sale of certain auction rate securities.

Loss on Impairment of Marketable Investment Securities. We recorded a loss on impairment of marketable investments securities of \$0 and \$2.2 million for the six months ended June 30, 2010 and 2009, respectively, related to other-than-temporary declines in fair value of our auction rate securities.

Income Taxes. We reported an income tax benefit of \$0 and \$1.0 million for the six months ended June 30, 2010 and 2009, respectively. The income tax benefit in 2009 primarily related to the recognition of tax credits from the Canadian province of Quebec for research and development activities for which the statute of limitations expired.

Liquidity and Capital Resources

The following table summarizes selected financial data (amounts in thousands):

	June 30, 2010	December 31, 2009
Cash, cash equivalents, and current marketable investment securities	\$ 133,241	\$ 74,928
Total assets	193,779	159,592
Current debt	27,827	48,514
Non-current debt	309,996	290,194
Stockholders' deficit	\$ (179,517)	\$ (222,799)

Currently, we are not a self-sustaining business and certain economic, operational and strategic factors may require us to secure additional funds. If we are unable to obtain sufficient funding at any time in the future, we may not be able to develop or commercialize our products, take advantage of business opportunities or respond to competitive pressures. Our current and anticipated operations require substantial capital. We expect that our existing capital resources including interest earned thereon will be sufficient to fund our current and planned operations through at least the next twelve months; however, our actual needs will depend on numerous factors, including the progress and scope of our internally funded development and commercialization activities; our ability to comply with the terms of our research funding agreements; our ability to maintain existing collaborations; our decision to seek additional collaborators; the success of our collaborators in developing and marketing products under their respective collaborations with us; our success in producing clinical and commercial supplies of our product candidates on a timely basis sufficient to meet the needs of our clinical trials and commercial launch; the costs we incur in obtaining and enforcing patent and other proprietary rights or gaining the freedom to operate under the patents of others; and our success in acquiring and integrating complementary products, technologies or businesses. Our clinical trials may be modified or terminated for several reasons including the risk that our product candidates will demonstrate safety concerns; the risk that regulatory authorities may not approve our product candidates for further development or may require additional or expanded clinical trials to be performed; and the risk that our manufacturers may not be able to supply sufficient quantities of our drug candidates to support our clinical trials or commercial launch, which could lead to a disruption or cessation of the clinical trials or commercial activities. We may also be required to conduct unanticipated preclinical or clinical trials to obtain regulatory approval of our product candidates, teduglutide and NPSP558. If any of the events that pose these risks comes to fruition, our actual capital needs may substantially exceed our anticipated capital needs and we may have to substantially modify or terminate current and planned clinical trials or postpone conducting future clinical trials. As a result, our business may be materially harmed, our stock price may be adversely affected, and our ability to raise additional capital may be impaired.

We will need to raise additional funds to support our long-term research, product development, and commercialization programs. We regularly consider various fund raising alternatives, including, for example, partnering of existing programs, monetizing of potential revenue streams, debt or equity financing and merger and acquisition alternatives. We may also seek additional funding through strategic alliances, collaborations, or license

agreements and other financing mechanisms. There can be no assurance that additional financing will be available on acceptable terms, if at all. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research and development programs, or to obtain funds through arrangements with licensees or others that may require us to relinquish rights to certain of our technologies or product candidates that we may otherwise seek to develop or commercialize on our own.

We require cash to fund our operating expenses, to make capital expenditures, acquisitions and investments and to service our debt. We have financed operations since inception primarily through payments received under collaborative research and license agreements, the private and public issuance and sale of equity securities, and the issuance and sale of non-recourse debt, convertible debt and lease financing. Through June 30, 2010, we have recognized \$478.1 million of cumulative revenues from payments for research support, license fees, product sales, milestone and royalty payments, \$621.5 million from the sale of equity securities for cash and \$593.6 million from the sale of non-recourse debt and convertible debt for cash.

Our principal sources of liquidity are cash, cash equivalents, and marketable investment securities, which totaled \$133.2 million at June 30, 2010. The primary objectives for our marketable investment security portfolio are liquidity and safety of principal. Investments are intended to achieve the highest rate of return to us, consistent with these two objectives. Our investment policy limits investments to certain types of instruments issued by institutions with investment grade credit ratings and places restrictions on maturities and concentration by type and issuer.

In April 2010, we sold 10,350,000 shares of our common stock at a price of \$5.50 per share in an underwritten public offering. Net proceeds, after underwriting discounts and expenses, were approximately \$53.2 million.

In February 2010, we sold all our remaining auction rate securities, except those subject to the settlement, to a third-party. These auction rate securities, which had a cost basis of \$4.6 million at December 31, 2009, were sold for \$8.2 million in total.

In February 2010, we sold our royalty rights from sales of REGPARA[®] (cinacalcet HCl) by Kyowa Hakko Kirin to DRI for \$38.4 million. Royalties will revert to us once DRI receives cumulative royalties of \$96 million. Under the agreement, DRI is entitled to receive royalty payments related to net sales of REGPARA occurring on or after July 1, 2009, including the \$2.1 million receivable from Kyowa Hakko Kirin we have recorded at December 31, 2009, which was paid to DRI in March 2010.

In August 2009, we entered into an equity line of credit arrangement with Azimuth Opportunity Ltd. (“Azimuth”), which provides that, upon the terms and subject to the conditions set forth therein, Azimuth is committed to purchase up to \$40,000,000 of our common stock, or the number of shares which is one share less than twenty percent (20%) of the issued and outstanding shares of our common stock as of August 5, 2009 (subject to automatic reduction in certain circumstances), at varying price discounts of up to 5% as defined, over the 18-month term of this agreement. We are not obligated to utilize this facility but if we elect to make a draw under this facility, the timing, dollar amount, and floor price per share are at the sole discretion of NPS, subject to certain limits as to the price per share and the draw down amounts. Azimuth is permitted to terminate this agreement under certain circumstances. In September 2009, Azimuth purchased 842,511 shares of our common stock under this agreement at an aggregate purchase price of \$3.5 million.

The following table summarizes our cash flow activity for the six months ended June 30, 2010 and 2009 (amounts in thousands):

	Six Months Ended	
	June 30,	
	2010	2009
Net cash used in operating activities	\$ (10,197)	\$ (5,390)
Net cash used in investing activities	\$ (6,917)	\$ (11,279)
Net cash provided by (used in) financing activities	\$ 68,085	\$ (7,935)

Net cash used in operating activities was \$10.2 million for the six months ended June 30, 2010 compared to \$5.4 million for the six months ended June 30, 2009. The net cash used was primarily related to the increased spending in research and development due to the advancement of our registration programs for teduglutide and NPS558.

Net cash used in investing activities was \$7.0 million and \$11.3 million during the six months ended June 30, 2010 and 2009, respectively. The net cash used in investing activities was primarily the result of investing excess cash not currently required to fund operations. Capital expenditures for the six months ended June 30, 2010 and 2009 were \$166,000 and \$240,000, respectively.

Net cash provided by financing activities was \$68.1 million during six months ended June 30, 2010 compared to cash used in financing activities of \$7.9 million during the six months ended June 30, 2009. Cash provided by financing activities during the six months ended June 30, 2010 primarily consisted of the \$53.2 million received from the public sale of common shares in April 2010 and the \$38.4 million received from the sale of REGPARA royalty rights to DRI Capital. The decrease in our restricted cash balance of \$26.7 million was due to making principal and cash sweep premium payments on our Class A Notes net of increases from cash received for royalty payments. These were offset by principal payments of \$50.7 million on our Class A Notes, DRI REGPARA Notes and capital lease obligation. Cash used in financing activities during the six months ended June 30, 2009 primarily relates to principal payments of \$35.4 million on our Class A Notes and capital lease obligations offset by reductions in our restricted cash balance related to our Class A Notes of \$27.3 million. Additionally, we received cash from the exercise of employee stock options of approximately \$669,000 and \$172,000 during the six months ended June 30, 2010 and 2009, respectively.

We could receive future milestone payments from all our agreements of up to \$216.6 million in the aggregate if each of our current licensees accomplishes the specified research and/or development milestones provided in the respective agreements. In addition, all of the agreements require the licensees to make royalty payments to us if they sell products covered by the terms of our license agreements; however, we do not control the subject matter, timing or resources applied by our licensees to their development programs. Thus, potential receipt of milestone and royalty payments from these licensees is largely beyond our control. Each of these agreements may be terminated before its scheduled expiration date by the respective licensee either for any reason or under certain conditions.

We have entered into certain research and license agreements that require us to make research support payments to academic or research institutions when the research is performed. Additional payments may be required upon the accomplishment of research milestones by the institutions or as license fees or royalties to maintain the licenses. As of June 30, 2010, we have a total commitment of up to \$512,000 for future research support and milestone payments. Further, depending on the commercial success of certain of our products, we may be required to pay license fees or royalties. For example, we are required to make royalty payments to certain licensors on teduglutide net sales and cinacalcet HCl royalty revenues. We expect to enter into additional sponsored research and license agreements in the future.

We have entered into long-term agreements with certain manufacturers and suppliers that require us to make contractual payment to these organizations. We expect to enter into collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require up-front payments and long-term commitments of cash.

Critical Accounting Policies and Estimates

For a discussion our critical accounting policies, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2009 Form 10-K.

New Accounting Standards

Refer to Notes 3 and 13 in “Notes to Condensed Consolidated Financial Statements” for a discussion of new accounting standards.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Interest Rate Risk. Our interest rate risk exposure results from our investment portfolio, our convertible notes, and our non-recourse notes. Our primary objectives in managing our investment portfolio are to preserve principal, maintain proper liquidity to meet operating needs and maximize yields. The securities we hold in our investment portfolio are subject to interest rate risk. At any time, significant changes in interest rates can affect the fair value of the investment portfolio and its interest earnings. For certain securities, such as auction rate securities, there are limits on the interest rate these securities can pay contractually. Increases in interest rates in excess of these contractual limits could cause the value of our investments to decline. After a review of our marketable

investment securities, we believe that in the event of a hypothetical ten percent increase in interest rates, the resulting decrease in fair market value of our marketable investment securities would be insignificant to the consolidated financial statements. Currently, we do not hedge these interest rate exposures. We have established policies and procedures to manage exposure to fluctuations in interest rates. We place our investments with high quality issuers and limit the amount of credit exposure to any one issuer and do not use derivative financial instruments in our investment portfolio. We invest in highly liquid, investment-grade securities and money market funds of various issues, types and maturities. These securities are classified as available for sale and, consequently, are recorded on the balance sheet at fair value with unrealized gains or losses reported as accumulated other comprehensive income as a separate component in stockholders' deficit, unless a loss is considered other than temporary, in which case the loss is recognized in earnings.

Our 5.75% Convertible Notes due 2014, our 8.0% non-recourse Class A Notes due 2017, and our 15.5% non-recourse Class B Notes due 2017, each have a fixed interest rate. As of June 30, 2010, our Convertible Notes, Class A Notes and Class B Notes had \$50.0 million, \$46.2 million and \$155.4 million, respectively, in aggregate principal amount outstanding. The fair value of the Convertible Notes is affected by changes in the interest rates and by changes in the price of our common stock. The fair value of the Class A Notes and Class B Notes are affected by changes in interest rates and by historical and projected rates of royalty revenues from cinacalcet HCl sales.

Foreign Currency Risk. We have significant clinical and commercial manufacturing agreements which are denominated in Euros and Canadian Dollars. As a result, our financial results could be affected by factors such as a change in the foreign currency exchange rate between the U.S. dollar and the Canadian dollar or Euro, or by weak economic conditions in Canada or Europe. When the U.S. dollar strengthens against the Canadian dollar or Euros, the cost of expenses in Canada or Europe decreases. When the U.S. dollar weakens against the Canadian dollar or Euro, the cost of expenses in Canada or Europe increases. The monetary assets and liabilities in our foreign subsidiary which are impacted by the foreign currency fluctuations are cash, accounts payable, and certain accrued liabilities. A hypothetical ten percent increase or decrease in the exchange rate between the U.S. dollar and the Canadian dollar or Euro from the June 30, 2010 rate would cause the fair value of such monetary assets and liabilities in our foreign subsidiary to change by an insignificant amount. We are not currently engaged in any foreign currency hedging activities.

Item 4. Controls and Procedures.

We maintain "disclosure controls and procedures" within the meaning of Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our disclosure controls and procedures, or Disclosure Controls, are designed to ensure that information required to be disclosed by us in the reports we file under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission's rules and forms. Our Disclosure Controls are also designed to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our Disclosure Controls, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating and implementing possible controls and procedures.

Evaluation of Disclosure Controls and Procedures. As of June 30, 2010, we evaluated the effectiveness of the design and operation of the Company's disclosure controls and procedures, which was done under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer. Immediately following the Signatures section of the Quarterly report on Form 10-Q are certifications of our Chief Executive Officer and Chief Financial Officer, which are required in accordance with Rule 13a-14 of the Exchange Act. This Controls and Procedures section includes the information concerning the controls evaluation referred to in the certifications and it should be read in conjunction with the certifications for a more complete understanding of the topics presented. Based on the controls evaluation, our Chief Executive Officer and Chief Financial Officer concluded that as of the date of their evaluation, our disclosure controls and procedures were effective to accomplish their intended purpose.

Change in Internal Control over Financial Reporting. There have been no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

Item 1. Legal Proceedings.

Refer to Note 10, *Legal Proceedings*, in “Notes to Condensed Consolidated Financial Statements” in Part I of this quarterly report on Form 10-Q, which is incorporated into this item by reference.

Item 1A. Risk Factors.

Other than the risk factor below, there have been no material changes to the risk factors as set forth in the Company's Annual Report filed on Form 10-K for the year ended December 31, 2009. The following risk factor is amended and restated in its entirety:

Because of the uncertainty of pharmaceutical pricing, reimbursement and healthcare reform measures, we or our licensees may be unable to sell our products profitably.

The availability of reimbursement by governmental and other third-party payers affects the market for any pharmaceutical product. These third-party payers continually attempt to contain or reduce the costs of healthcare. There have been a number of legislative and regulatory proposals to change the healthcare system and further proposals are likely. Medicare's policies may decrease the market for our products. Significant uncertainty exists with respect to the reimbursement status of newly approved healthcare products.

In addition, third-party payers are increasingly challenging the price and cost-effectiveness of medical products and services. We might not be able to sell our products profitably or recoup the value of our investment in product development if reimbursement is unavailable or limited in scope, particularly for product candidates addressing small patient populations, such as teduglutide for the treatment of short bowel syndrome and NPSP558 for hypoparathyroidism.

In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. We expect that there will continue to be a number of U.S. federal and state proposals to implement governmental pricing controls. While we cannot predict whether such legislative or regulatory proposals will be adopted, the adoption of such proposals could have a material adverse effect on our business, financial condition and profitability.

On July 15, 2008, the Medicare Improvements for Patients and Providers Act of 2008 became law with a number of Medicare and Medicaid reforms to establish a bundled Medicare payment rate that includes services and drug/labs that are currently separately billed. A recent rule by the Centers for Medicare and Medicaid Services requires the inclusion of certain oral drugs such as Sensipar® (cinacalcet HCl) as part of the end stage renal disease Program of Medicare bundled payment beginning in 2014. Bundling initiatives that have been implemented in other healthcare settings have occasionally resulted in lower utilization of services that had not previously been a part of the bundled payment. We cannot speculate on the sales impact to Sensipar based on the new rule.

Item 6. Exhibits.

(a) *Exhibits:*

<u>Exhibit Number</u>	<u>Description of Document</u>
10.1(1)	NPS Pharmaceuticals, Inc. 2010 Employee Stock Purchase Plan
31.1	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
31.2	Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
32	Section 1350 Certification of Periodic Financial Report by the Chief Executive Officer and Chief Financial Officer

(1) Incorporated herein by reference to the Registrant's Current Report on Form 8-K, filed on May 24, 2010 (SEC File No. 000-23272).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NPS PHARMACEUTICALS, INC.

Date: August 4, 2010

By: /s/ Francois Nader
Francois Nader,
President and Chief Executive Officer (Principal Executive Officer)

Date: August 4, 2010

By: /s/ Luke M. Beshar
Luke M. Beshar,
Chief Financial Officer (Principal Financial and Accounting Officer)

EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Description of Document</u>
10.1(1)	NPS Pharmaceuticals, Inc. 2010 Employee Stock Purchase Plan
31.1	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
31.2	Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
32	Section 1350 Certification of Periodic Financial Report by the Chief Executive Officer and Chief Financial Officer

(1) Incorporated herein by reference to the Registrant's Current Report on Form 8-K, filed on May 24, 2010 (SEC File No. 000-23272).